Superficial and @entity1150 , XXXX and subsequent risk of @entity5 .

@entity1 @entity5 @entity49 @entity1151 @entity1150 @entity1031 @entity1893
BACKGROUND: In contrast to @entity1150 and @entity1151 , @entity49 has not been considered to be a marker of @entity5 . However, actual data regarding the association are very limited. METHODS: We identified all @entity1 in Denmark from 1994 to 2009 with a diagnosis of @entity49 , @entity1150 using population-based health registries. The occurrence of @entity5 in the three venous @entity1031 cohorts was compared with the expected numbers of cases estimated using national incidence rates to compute standardised incidence ratios (SIRs). FINDINGS: We identified a total of 7663 @entity1 with @entity49 , 45,252 with @entity1150 and 24,332 with @entity1151 . In the first year of follow-up, very similar proportions of @entity1 in the three cohorts were diagnosed with @entity5 . The SIR was 2.46 (95% CI, 2.10-2.86) for @entity49 , 2.75 (95% CI, 2.60-2.90) for @entity1150 , and 3.27 (95% CI, 3.03-3.52) for @entity1151 . After one year, the SIRs declined to 1.05 (95% CI, 0.96-1.16), 1.11 (95% CI 1.07-1.16) and 1.15 (95% CI, 1.09-1.22), respectively. For all three @entity1 cohorts, particularly strong associations were found for @entity5 of the liver, lung, ovaries and pancreas as well as for @entity1893 . INTERPRETATION: @entity49 , whenever it is seen in the lower limbs, is a preclinical marker of prevalent @entity5 , particularly during the first year after diagnosis.
